Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
Edgewise Therapeutics and IDEAYA Biosciences released annual financial reports detailing clinical trial progress and strategic initiatives. Both companies are advancing multiple clinical-stage programs while managing significant operating expenses.
Teva and Sanofi reported positive 44-week data from the RELIEVE UCCD long-term extension study of duvakitug, showing durable efficacy in ulcerative colitis and Crohn's disease patients.
New data from LIBERTY studies show subcutaneous infliximab effectively restored and maintained disease control in Crohn's disease and ulcerative colitis patients after drug holiday of 16 weeks or more, with sustained efficacy through Week 102.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07435779 |
Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study |
RECRUITING | EARLY_PHASE1 |
| NCT02393248 |
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) |
TERMINATED | PHASE1/PHASE2 |
